• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Connect Biopharma Holdings Limited - Ordinary Shares (NQ:CNTB)

0.9270 -0.0527 (-5.38%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,196,128
Open 0.9800
Bid (Size) 0.9260 (2,200)
Ask (Size) 0.9270 (600)
Prev. Close 0.9797
Today's Range 0.8860 - 1.080
52wk Range 0.8860 - 3.820
Shares Outstanding 55,041,247
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session. ↗
September 30, 2026
Via Chartmill
Discover the most active stocks in Wednesday's session. ↗
September 30, 2026
Via Chartmill

Performance

52-Week Range 75.7% below 52-week high
0.9270
0.8952W Low 3.8252W High
1 Week 51.0% below 1-week high
0.891W Low 1.891W High

Connect Biopharma Holdings Limited - Ordinary Shares (CNTB) traded between $0.89 and $3.82 over the past 52 weeks and last traded at $0.93, 75.7% below its 52-week high. Over the past week it ranged between $0.89 and $1.89.

Past 12 Months
-14.2%
-66.4%
-60.7%
-67.6%
-63.2%
-33.3%
1W -$0.15
1M -$1.83
3M -$1.43
6M -$1.93
YTD -$1.59
1Y -$0.46

CNTB was -33.3% over the past year, -67.6% over six months, -63.2% year to date, -14.2% in the last week.

12 Months vs Market
CNTB
-33.3%
DIA
+9.9%
SPY
+15.0%
QQQ
+23.7%
IWM
+15.4%

Over the past 12 months CNTB returned -33.3% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity 1.11× 3-mo avg
Today 4,196,128 3-mo avg 3.8M
1W
36.3M
1M
10.0M
3M
3.8M
6M
2.1M
YTD
1.4M
1Y
1.1M

CNTB most recently traded 4,196,128 shares against a 3-month average daily volume of 3.8M.

More News

Read More
Let's take a look at the stocks that are in motion in today's session. ↗
September 30, 2026
Via Chartmill
Which stocks are gapping on Wednesday? ↗
September 30, 2026
Via Chartmill
Wednesday's pre-market session: top gainers and losers ↗
September 30, 2026
Via Chartmill
News headline image
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
September 30, 2026
From Connect Biopharma Holdings Limited
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
September 15, 2026
Via Chartmill
Keep an eye on the top gainers and losers in Tuesday's session. ↗
September 15, 2026
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
September 15, 2026
Via Chartmill
What's going on in today's pre-market session ↗
September 15, 2026
Via Chartmill
News headline image
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
September 15, 2026
From Connect Biopharma Holdings Limited
Via GlobeNewswire
These stocks are moving in today's after hours session ↗
September 03, 2026
Via Chartmill
News headline image
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 03, 2026
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
August 12, 2026
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
June 17, 2026
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026 ↗
May 22, 2026
Via MarketBeat
News headline image
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
May 12, 2026
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
April 23, 2026
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
April 07, 2026
Via ACCESS Newswire
Wondering what's happening in today's after-hours session? ↗
April 01, 2026
Via Chartmill
News headline image
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
March 31, 2026
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces $20.2 Million Private Placement Financing
March 30, 2026
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
March 30, 2026
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
March 30, 2026
From Connect Biopharma Holdings Limited
Via GlobeNewswire

Frequently Asked Questions

Is Connect Biopharma Holdings Limited - Ordinary Shares publicly traded?
Yes, Connect Biopharma Holdings Limited - Ordinary Shares is publicly traded.
What exchange does Connect Biopharma Holdings Limited - Ordinary Shares trade on?
Connect Biopharma Holdings Limited - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Connect Biopharma Holdings Limited - Ordinary Shares?
The ticker symbol for Connect Biopharma Holdings Limited - Ordinary Shares is CNTB on the Nasdaq Stock Market
What is the current price of Connect Biopharma Holdings Limited - Ordinary Shares?
The current price of Connect Biopharma Holdings Limited - Ordinary Shares is 0.9270
When was Connect Biopharma Holdings Limited - Ordinary Shares last traded?
The last trade of Connect Biopharma Holdings Limited - Ordinary Shares was at 10/02/26 04:00 PM ET
What is the market capitalization of Connect Biopharma Holdings Limited - Ordinary Shares?
The market capitalization of Connect Biopharma Holdings Limited - Ordinary Shares is 51.02M
How many shares of Connect Biopharma Holdings Limited - Ordinary Shares are outstanding?
Connect Biopharma Holdings Limited - Ordinary Shares has 51M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap